TWI632162B - Ｕｂｅ２ｔ胜肽與含此之疫苗 - Google Patents

Ｕｂｅ２ｔ胜肽與含此之疫苗 Download PDF

Info

Publication number
TWI632162B
TWI632162B TW102132531A TW102132531A TWI632162B TW I632162 B TWI632162 B TW I632162B TW 102132531 A TW102132531 A TW 102132531A TW 102132531 A TW102132531 A TW 102132531A TW I632162 B TWI632162 B TW I632162B
Authority
TW
Taiwan
Prior art keywords
peptide
ube2t
antigen
cytotoxic
present
Prior art date
Application number
TW102132531A
Other languages
English (en)
Chinese (zh)
Other versions
TW201414752A (zh
Inventor
角田卓也
Takuya Tsunoda
大沢龍司
Ryuji Osawa
吉村祥子
Sachiko Yoshimura
渡辺朝久
Tomohisa Watanabe
Original Assignee
日商腫瘤療法 科學股份有限公司
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商腫瘤療法 科學股份有限公司, Oncotherapy Science, Inc. filed Critical 日商腫瘤療法 科學股份有限公司
Publication of TW201414752A publication Critical patent/TW201414752A/zh
Application granted granted Critical
Publication of TWI632162B publication Critical patent/TWI632162B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
TW102132531A 2012-09-11 2013-09-10 Ｕｂｅ２ｔ胜肽與含此之疫苗 TWI632162B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699550P 2012-09-11 2012-09-11
US61/699,550 2012-09-11

Publications (2)

Publication Number Publication Date
TW201414752A TW201414752A (zh) 2014-04-16
TWI632162B true TWI632162B (zh) 2018-08-11

Family

ID=50277926

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102132531A TWI632162B (zh) 2012-09-11 2013-09-10 Ｕｂｅ２ｔ胜肽與含此之疫苗

Country Status (17)

Country Link
US (2) US10092634B2 (https=)
EP (1) EP2895600B1 (https=)
JP (1) JP6283861B2 (https=)
KR (1) KR102110873B1 (https=)
CN (2) CN104619833B (https=)
AU (1) AU2013317194B2 (https=)
BR (1) BR112015004349B1 (https=)
CA (1) CA2873155C (https=)
DK (1) DK2895600T3 (https=)
ES (1) ES2784862T3 (https=)
IL (1) IL236690B (https=)
MX (1) MX362912B (https=)
PL (1) PL2895600T3 (https=)
RU (1) RU2663350C2 (https=)
SG (2) SG10201701866QA (https=)
TW (1) TWI632162B (https=)
WO (1) WO2014041784A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
JP6715004B2 (ja) 2015-12-25 2020-07-01 宏 半田 免疫賦活化剤およびその製造方法
EP4649954A3 (en) 2017-01-25 2025-12-17 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
EP3691662A4 (en) * 2017-10-06 2021-05-12 The University of Chicago SCREENING OF T LYMPHOCYTE FOR CANCER SPECIFIC ANTIGENS
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113679829B (zh) 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1306431A1 (en) * 2000-07-31 2003-05-02 Kyogo Itoh Tumor antigen
WO2009001562A1 (en) * 2007-06-27 2008-12-31 Oncotherapy Science, Inc. Compositions and methods of treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
CN100419079C (zh) 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
US20070202109A1 (en) 2003-09-24 2007-08-30 Oncotherapy Science, Inc. Method Of Diagnosing Breast Cancer
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2340851A4 (en) 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
TWI539160B (zh) * 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
WO2010073551A1 (en) * 2008-12-24 2010-07-01 Oncotherapy Science, Inc. C1orf59 peptides and vaccines including the same
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
TW201216982A (en) * 2010-10-21 2012-05-01 Oncotherapy Science Inc WDHD1 peptides and vaccines including the same
EP2630237A4 (en) * 2010-10-21 2014-04-09 Oncotherapy Science Inc C18ORF54 PEPTIDES AND VACCINES CONTAINING THEM
SG190407A1 (en) * 2010-12-02 2013-06-28 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1306431A1 (en) * 2000-07-31 2003-05-02 Kyogo Itoh Tumor antigen
WO2009001562A1 (en) * 2007-06-27 2008-12-31 Oncotherapy Science, Inc. Compositions and methods of treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
2006年08月18日，UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation，Mol Cell. 2006 Aug;23(4):589-96.
年08月18日，UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation，Mol Cell. 2006 Aug;23(4):589-96. *

Also Published As

Publication number Publication date
BR112015004349A2 (pt) 2017-08-08
KR102110873B1 (ko) 2020-05-14
CA2873155C (en) 2022-07-26
RU2663350C2 (ru) 2018-08-03
CA2873155A1 (en) 2014-03-20
TW201414752A (zh) 2014-04-16
US20180360938A1 (en) 2018-12-20
AU2013317194B2 (en) 2018-07-12
KR20150054710A (ko) 2015-05-20
EP2895600B1 (en) 2020-02-19
MX2015003017A (es) 2015-06-10
CN104619833B (zh) 2018-01-02
CN107881158B (zh) 2021-11-16
BR112015004349B1 (pt) 2022-11-01
CN107881158A (zh) 2018-04-06
ES2784862T3 (es) 2020-10-01
MX362912B (es) 2019-02-22
DK2895600T3 (da) 2020-04-27
JP2015529219A (ja) 2015-10-05
CN104619833A (zh) 2015-05-13
US10092634B2 (en) 2018-10-09
EP2895600A4 (en) 2016-05-04
AU2013317194A1 (en) 2015-02-05
WO2014041784A1 (en) 2014-03-20
EP2895600A1 (en) 2015-07-22
US20150174223A1 (en) 2015-06-25
IL236690B (en) 2021-03-25
JP6283861B2 (ja) 2018-02-28
HK1212730A1 (en) 2016-06-17
SG11201501761SA (en) 2015-04-29
PL2895600T3 (pl) 2020-10-05
US11266729B2 (en) 2022-03-08
RU2015113436A (ru) 2016-11-10
SG10201701866QA (en) 2017-04-27
IL236690A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
TWI658049B (zh) Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US11266729B2 (en) UBE2T peptides and vaccines containing the same
TWI617582B (zh) Ｔｏｐｋ胜肽及含其之疫苗
TWI485245B (zh) 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
CN102947325B (zh) Cdca5肽及包含它们的疫苗
TWI564303B (zh) Ｍｐｈｏｓｐｈ１胜肽及含其之疫苗
TW201302800A (zh) Ｓｅｍａ５ｂ胜肽及含其之疫苗
CN103339253B (zh) Tomm34肽及包含它们的疫苗
CN103189510B (zh) Ttll4肽及包含它们的疫苗
CN105601727B (zh) Hjurp肽及包含它们的疫苗
CN102939379B (zh) Ect2肽及包含它们的疫苗
WO2011074236A1 (en) Tmem22 peptides and vaccines including the same
CN103282494B (zh) C18orf54肽及包含它们的疫苗
CN103270156B (zh) Wdhd1肽及包含它们的疫苗
TW201431874A (zh) Ｓｅｍａ５ｂ胜肽與含此之疫苗
TW201439114A (zh) Ｃｄｃａ５胜肽及含此胜肽之疫苗
TW201443078A (zh) Ｃ１２ｏｒｆ４８胜肽及含此胜肽之疫苗
HK1212730B (en) Ube2t peptides and vaccines containing the same

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees